Literature DB >> 33347692

Co-expression of IL-7 and PH20 promote anti-GPC3 CAR-T tumour suppressor activity in vivo and in vitro.

Xingcheng Xiong1, Juanli Xi2, Qian Liu3, Cixiao Wang4, Zeyou Jiang3, Su-Yang Yue5, Lei Shi6, Yuping Rong1.   

Abstract

BACKGROUND: While CAR-T therapy has successfully treated haematological malignancies, it has proved sub-optimal for solid tumours. The main limitation is the inability of CAR-T cells to infiltrate and then proliferate within tumours.
METHOD: We co-expressed IL-7 and PH20, a type of hyaluronidase, with CAR targeting GPC3 (G3CAR-7 × 20). We test the anti-tumour ability in vitro and in vivo. Moreover the capacity of infiltration and proliferation of G3CAR-7 × 20 was measured. RESULT: We found (G3CAR-7 × 20) exhibited better proliferation in vivo and in vitro than G3CAR, reduced the level of apoptosis after stimulation by tumour cells, and maintained the memory phenotype of CAR-T cells. G3CAR-7 × 20 also increased the ability of CAR-T cells to infiltrate tumour tissue.
CONCLUSION: co-expressed IL-7 and PH20 may significantly enhance the efficacy of targeted GPC3 CAR-T cells in solid tumours treatment.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  CAR-T; IL-7; PH20; memory T cell

Mesh:

Substances:

Year:  2021        PMID: 33347692     DOI: 10.1111/liv.14771

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

Review 1.  Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.

Authors:  Alain E Andrea; Andrada Chiron; Sarah Mallah; Stéphanie Bessoles; Guillaume Sarrabayrouse; Salima Hacein-Bey-Abina
Journal:  Front Immunol       Date:  2022-02-08       Impact factor: 7.561

Review 2.  CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future.

Authors:  Zhengchao Zhang; Dong Li; Heng Yun; Wei Liu; Keqiang Chai; Jie Tong; Tongwei Zeng; Zhenghua Gao; Yongqiang Xie
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

Review 3.  Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma.

Authors:  Xiufeng Zheng; Xun Liu; Yanna Lei; Gang Wang; Ming Liu
Journal:  Front Oncol       Date:  2022-02-16       Impact factor: 6.244

Review 4.  Emerging Strategies in TCR-Engineered T Cells.

Authors:  Fang Wei; Xiao-Xia Cheng; John Zhao Xue; Shao-An Xue
Journal:  Front Immunol       Date:  2022-03-30       Impact factor: 7.561

5.  Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.

Authors:  Hongwei Sun; Chongyun Xing; Songfu Jiang; Kang Yu; Shengjie Dai; Hongru Kong; Yuepeng Jin; Yunfeng Shan; Wenjun Yang; Zhen Wang; Jun Xiao; Huamao Wang; Wei Wang; Zonghai Li; Keqing Shi
Journal:  Front Immunol       Date:  2022-08-17       Impact factor: 8.786

Review 6.  Gene-Edited Interleukin CAR-T Cells Therapy in the Treatment of Malignancies: Present and Future.

Authors:  Zhengchao Zhang; Lele Miao; Zhijian Ren; Futian Tang; Yumin Li
Journal:  Front Immunol       Date:  2021-07-27       Impact factor: 7.561

7.  Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric Cancer.

Authors:  Ruocong Zhao; Yuanbin Cui; Yongfang Zheng; Shanglin Li; Jiang Lv; Qiting Wu; Youguo Long; Suna Wang; Yao Yao; Wei Wei; Jie Yang; Bin-Chao Wang; Zhenfeng Zhang; Hui Zeng; Yangqiu Li; Peng Li
Journal:  Front Immunol       Date:  2021-07-13       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.